Quality of compounded hydrocortisone capsules used in the treatment of children
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Due to the lack of paediatric-licensed formulations, children are often treated with individualized pharmacy-compounded adult medication. An international web-based survey about the types of medication in children with adrenal insufficiency (AI) revealed that the majority of paediatric physicians are using pharmacy-compounded medication to treat children with AI. Observations of loss of therapy control in children with congenital adrenal hyperplasia with compounded hydrocortisone capsules and regained control after prescribing a new hydrocortisone batch led to this 'real world' evaluation of pharmacy-compounded paediatric hydrocortisone capsules. METHODS: Capsule samples were collected randomly from volunteering parents of treated children suffering from congenital adrenal hyperplasia from all over Germany. Analysis of net mass and hydrocortisone content by high-performance liquid chromatography with ultraviolet (HPLC-UV) detection method was performed based on the European Pharmacopeia. RESULTS: In a total of 61 batches that were sent, 5 batches could not be analysed because of missing dose information, insufficient number of capsules or were not possible to be evaluated. Fifty-six batches containing 1125 capsules were evaluated. 21.4% of the batches revealed insufficiency in uniformity of net mass or drug content and additional 3.6% failed because they did not contain the labelled drug. CONCLUSIONS: Compounded medication is a possible cause of variation of steroid doses in children with adrenal insufficiency or congenital adrenal hyperplasia, putting these vulnerable patients at risk of poor disease control and adrenal crisis. These data may apply to other individualized compounded oral medication as well, emphasizing the need for development of licensed paediatric formulations approved by regulatory authorities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Availability of pediatric dose formulations would eliminate concerns about improper compounding of HC from tablets (192)(193)(194).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [192]
Experimental — accuracy not yet measuredIn the citing paper
“A recent study, reported that 21.4% of pharmacist-compounded hydrocortisone batches failed to meet European pharmacopeia guidelines and a further 3.6% of batches contained no hydrocortisone (7).”
From Immediate-release granule formulation of hydrocortisone, Alkindi®, for treatment of paediatric adrenal insufficiency (Infacort development programme) (2018) · cites this paper as [7]
In the citing paper
“The inconsistency in hydrocortisone dose created by compounding can lead to severe clinical consequences with poor disease control due to undertreatment (7) and Cushings syndrome due to overtreatment (11,12).”
From Immediate-release granule formulation of hydrocortisone, Alkindi®, for treatment of paediatric adrenal insufficiency (Infacort development programme) (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survey of unlicensed and off label drug use in paediatric wards in European countries
Conroy, S. (2000) · BMJ · doi:10.1136/bmj.320.7227.79 · Cited by 735
Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313
Potential risks of pharmacy compounding
Gudeman, J., Jozwiakowski, M., Chollet, J., & Randell, M. (2013) · Drugs in R&D · doi:10.1007/s40268-013-0005-9 · Cited by 196
Han, T. S., Conway, G. S., Willis, D. S., Krone, N., Rees, D. A., Stimson, R. H., Arlt, W., Walker, B. R., Ross, R. J., & (CaHASE), T. U. K. C. A. H. A. S. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1486 · Cited by 65
Self-citationWhitaker, M. J., Spielmann, S., Digweed, D., Huatan, H., Eckland, D., Johnson, T. N., Tucker, G., Krude, H., Blankenstein, O., & Ross, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4060 · Cited by 48
Self-citationClinical Setting Influences Off-Label and Unlicensed Prescribing in a Paediatric Teaching Hospital
Czarniak, P., Bint, L. J., Favié, L. M. A., Parsons, R. W., Hughes, J., & Sunderland, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120630 · Cited by 43
Research works printed but not linked: 8
- 2015, Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency, Journal of Clinical Endocrinology and Metabolism, 100, 1681, 10.1210/jc.2014-4060 · DOI · Paper page
- 2015, Clinical setting influences off-label and unlicensed prescribing in a paediatric teaching hospital, PLoS ONE, 10, e0120630, 10.1371/journal.pone.0120630 · DOI
- CaHASE, Kingdom Congenital Adrenal Hyperplasia Adult Study Executive Relationship between final height and health outcomes in adults with congenital adrenal hyperplasia : United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive of Clinical Endocrinology, Journal Metabolism, 201499, 10.1210/jc.2014-1486 · DOI · Paper page
- 2013, HPLC method development to determine hydrocortisone from capsules contributing to a medication safety study., Annual Meeting of the German Pharmaceutical Society: DPhG
- 2012, Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia, Journal of Clinical Endocrinology and Metabolism, 97, 4429, 10.1210/jc.2012-2102 · DOI · Paper page
- 2013, HPLC method development to determine hydrocortisone from capsules contributing to a medication safety study., Annual Meeting of the German Pharmaceutical Society: DPhG
- 2000, Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children, BMJ, 320, 79, 10.1136/bmj.320.7227.79 · DOI · Paper page
- 2013, Potential risks of pharmacy compounding, Drugs in R&D, 13, 1, 10.1007/s40268-013-0005-9 · DOI · Paper page
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis
(MTG1), O. B. O. E. E., Nowotny, H. F., Ahmed, S. F., Bensing, S., Beun, J. G., Brösamle, M., Chifu, I. O., der Grinten, H. L. C., Clemente, M., Falhammar, H., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02649-6 · Cited by 104
Neumann, U., Whitaker, M. J., Wiegand, S., Krude, H., Porter, J., Davies, M., Digweed, D., Voet, B., Ross, R. J., & Blankenstein, O. (2018) · Clinical Endocrinology · doi:10.1111/cen.13447 · Cited by 64
Self-citation
Metadata
- Authors
- Neumann, U., Burau, D., Spielmann, S., Whitaker, M. J., Ross, R. J., Kloft, C., & Blankenstein, O.
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- Freie Universität Berlin (DE)
- University of Sheffield (GB)
- Corresponding author
- Blankenstein, Oliver
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08
- Volume
- 177
- Issue
- 2
- Pages
- 239-242
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2616786361
- Cited by
- 56
- References
- 6
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 8 · 2020: 5 · 2019: 7 · 2018: 6 · 2017: 2
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Journal of Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Funders
- European Commission (281654)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- cortisol, pharmaceutical compounding, congenital adrenal hyperplasia, adrenal insufficiency, drug quality, drug content uniformity, adrenal crisis, pediatric formulations
- MeSH terms
- Adrenal Insufficiency, Capsules, Chemistry, Pharmaceutical, Child, Dose-Response Relationship, Drug, Drug Compounding, Germany, Humans, Hydrocortisone, Random Allocation, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quality of compounded hydrocortisone capsules used in the treatment of children. https://app.cochat.ai/papers/10.1530/eje-17-0248
- The paper
- Neumann, U., Burau, D., Spielmann, S., Whitaker, M. J., Ross, R. J., Kloft, C., & Blankenstein, O. (2017). Quality of compounded hydrocortisone capsules used in the treatment of children. European Journal of Endocrinology. https://doi.org/10.1530/eje-17-0248
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
